{"id":538594,"date":"2021-09-15T09:03:24","date_gmt":"2021-09-15T13:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/"},"modified":"2021-09-15T09:03:24","modified_gmt":"2021-09-15T13:03:24","slug":"abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/","title":{"rendered":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines<\/b><\/p>\n<p class=\"bwalignc\"><i>Partnership combines AbCellera\u2019s AI-powered antibody discovery platform with Moderna\u2019s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications<\/i><\/p>\n<p>VANCOUVER, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com%2F&amp;esheet=52491918&amp;newsitemid=20210915005361&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=eb516b38c5eb0ad6b5242bd8c91ee0f8\">AbCellera<\/a> (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera\u2019s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.\n<\/p>\n<p>\n\u201cOver the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world,\u201d said Carl Hansen, Ph.D., CEO and President of AbCellera. \u201cWe are excited to work alongside their team to advance RNA-encoded antibodies as a new frontier in genetic medicines.\u201d\n<\/p>\n<p>\nUnder the terms of the agreement, Moderna will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Moderna downstream clinical and commercial milestone payments and royalties on net sales of products.\n<\/p>\n<p><b>About AbCellera Biologics Inc.<\/b><\/p>\n<p>\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com%2F&amp;esheet=52491918&amp;newsitemid=20210915005361&amp;lan=en-US&amp;anchor=www.abcellera.com&amp;index=2&amp;md5=b0ef0ddd6d458412a0828fabec252b76\">www.abcellera.com<\/a>.\n<\/p>\n<p><b>AbCellera Forward-looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.\n<\/p>\n<p>\nIn some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.\n<\/p>\n<p>\nSource: AbCellera Biologics Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210915005361\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210915005361\/en\/<\/a><\/span><\/p>\n<p><b>AbCellera Inquiries:<br \/>\n<\/b><br \/>Media: Jessica Yingling, Ph.D.; <a rel=\"nofollow\" href=\"mailto:media@abcellera.com\">media@abcellera.com<\/a>, +1(236) 521-6774<br \/>\n<br \/>Business Development: Neil Berkley; <a rel=\"nofollow\" href=\"mailto:bd@abcellera.com\">bd@abcellera.com<\/a>, +1(604) 559-9005<br \/>\n<br \/>Investor Relations: Melanie Solomon; <a rel=\"nofollow\" href=\"mailto:ir@abcellera.com\">ir@abcellera.com<\/a>, +1(778) 729-9116\n<\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Genetics Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210915005361\/en\/705128\/3\/AbCellera_Full_Colour_RGB_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines Partnership combines AbCellera\u2019s AI-powered antibody discovery platform with Moderna\u2019s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211;AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera\u2019s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna. \u201cOver the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world,\u201d said Carl Hansen, Ph.D., CEO and President of AbCellera. \u201cWe are excited to work alongside &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538594","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines Partnership combines AbCellera\u2019s AI-powered antibody discovery platform with Moderna\u2019s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211;AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera\u2019s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna. \u201cOver the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world,\u201d said Carl Hansen, Ph.D., CEO and President of AbCellera. \u201cWe are excited to work alongside &hellip; Continue reading &quot;AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-15T13:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines\",\"datePublished\":\"2021-09-15T13:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/\"},\"wordCount\":625,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/\",\"name\":\"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-09-15T13:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines - Market Newsdesk","og_description":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines Partnership combines AbCellera\u2019s AI-powered antibody discovery platform with Moderna\u2019s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211;AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera\u2019s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna. \u201cOver the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world,\u201d said Carl Hansen, Ph.D., CEO and President of AbCellera. \u201cWe are excited to work alongside &hellip; Continue reading \"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-15T13:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines","datePublished":"2021-09-15T13:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/"},"wordCount":625,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/","name":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-09-15T13:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210915005361r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-moderna-to-discover-therapeutic-antibodies-for-mrna-medicines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538594"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538594\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}